Description
Anti-interferon α/β receptor Antibody, Highly Galactosylated (BioBet-GA-266ZP) is a human IgG1, κ antibody against interferon α/β receptor which contains with a high level of galactosylation.
Antibody Indication
Diffuse scleroderma
Classification
Therapeutic antibody; biobetter
Cooperation Seeking
Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced interferon α/β receptor antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
IFNAR
Alternative Names
anifrolumab;1326232-46-5;MEDI-546;interferon-α/β receptor;IFNAR
Cellular Localization
Plasma membrane, Lysosome, Endosome
Genecards
5432
Involvement in Disease
Its related pathways are Immune response IFN alpha/beta signaling pathway and Immune response Role of DAP12 receptors in NK cells.
Related Pathways
The components of type I interferon receptors, including interferon alpha, IFNB1 and IFNW1. IFNAR2 is generally used as a heterodimer. Type I interferon binding activates the JAK-STAT signaling cascade and triggers the tyrosine phosphorylation of many proteins, including JAKs, TYK2, STAT proteins, and IFNR-and-subunits. It can form an active IFNB1 receptor on its own and activate a signal cascade that does not involve activation of the JAK-STAT pathway (through similarity).
Field of research
Ubiquitinated, leading to its internalization and degradation (PubMed:14532120, PubMed:15337770). Polyubiquitinated via 'Lys-48'-linked and 'Lys-63'-linked ubiquitin chains, leading to receptor internalization and lysosomal degradation (PubMed:18056411). The 'Lys-63'-linked ubiquitin chains are cleaved off by the BRISC complex (PubMed:24075985). Phosphorylated on serine residues in response to interferon binding; this promotes interaction with FBXW11 and ubiquitination (PubMed:14532120, PubMed:15337770, PubMed:24075985). Phosphorylated on tyrosine residues by TYK2 tyrosine kinase (PubMed:7526154). Phosphorylated on tyrosine residues in response to interferon (PubMed:10049744). Palmitoylation at Cys-463 is required for the activation of STAT1 and STAT2.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1, κ
Antibody Clone
BioBet-GA-266ZP
Description
Recombinant human monoclonal antibody expressed in CHO binding to human interferon α/β receptor. Anifrolumab is a monoclonal antibody designed for the treatment of systemic lupus erythematosus.
Antibody Indication
Diffuse scleroderma
